Cell Free DNA For EGFR (Del19, L858R, T790M), Blood

This test measures the following attributes:

• Detection of specific EGFR gene mutations in cell-free DNA
• Identification of Del19, L858R, and T790M mutations
• These mutations can determine the effectiveness of targeted therapies for cancers like non-small cell lung cancer.

Common reasons for conducting this test include:

• To predict the response to targeted therapies for lung cancer
• To monitor treatment effectiveness
• To detect drug resistance mutations
• To guide treatment decisions for lung cancer patients

This test is usually recommended:

• When non-small cell lung cancer is suspected
• If previous treatments have not been successful
• For patients showing signs of drug resistance
• Individuals requiring personalised treatment approaches based on genetic mutations

Normal results involve the absence of Del19, L858R, or T790M mutations. Abnormal results may indicate drug resistance or the need for alternative treatments. Your doctor will interpret results based on your medical history.

During the test:

• A blood sample will be collected from your arm.
• The process is quick and relatively painless.
• You may feel a slight pinch when the needle is inserted.

Prepare for the test by:

• Following any fasting instructions provided by your doctor
• Informing your doctor about any medications you are taking
• Ensure you have a histopathology report available

Other tests that may accompany this one include:

• Liquid biopsy: A test that looks for cell-free circulating tumor DNA in the blood
• Histopathology testing: Examination of tissues for microscopic changes indicating cancer

Cell-Free Circulating Tumor DNA Test or the Liquid Biopsy Test

Non-small cell lung cancer is commonly diagnosed after this test. It is a type of lung cancer that includes various subtypes like adenocarcinoma and squamous cell carcinoma. Testing helps tailor treatments for better outcomes.